Work

Relationship between apalutamide (APA) exposure and metastasis-free survival (MFS) in patients (pts) with nonmetastatic castration-resistant prostate cancer (nmCRPC) from SPARTAN

Year: 2018

Type: article

Abstract: Background: The phase 3 SPARTAN study evaluated the efficacy and safety of APA vs placebo (PBO) in men with high-risk nmCRPC. Because dose reductions/interruptions for the management of AEs that occur during treatment can affect drug efficacy, this analysis sought to understand the relationship of APA pharmacokinetic exposure and the primary end point of SPARTAN, MFS.

Source: Annals of Oncology

DOI: 10.1093/annonc/mdy284.015

Authors: M.R. Smith, C. Perez-Ruixo, O. Ackaert, D. Ouellet, C. Chien, H. Uemura, D. Olmos, P.N. Mainwaring, J.Y. Lee, M.K. Yu, J.-J. Perez-Ruixo, E.J. Small

Institutions: Harvard University, Massachusetts General Hospital, Janssen (Belgium), Yokohama City University Medical Center, Spanish National Cancer Research Centre, The University of Queensland, The Catholic University of Korea Seoul St. Mary's Hospital, Catholic University of Korea, University of California, San Francisco, UCSF Helen Diller Family Comprehensive Cancer Center

Language: English

Topic: Prostate Cancer Treatment and Research

Subfield: Pulmonary and Respiratory Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: hybrid

Estimated APC paid: $5,080

OpenAlex ID: W2898170204

FWCI: 0.19

Cites:

Cited by: 1

Related to: 10